secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001104659-24-033068
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute validates RZ358 for NICTH, doubling addressable tumor HI patient population
--------------------------------------------------------------------------------

- Preclinical study shows RZ358 blunts IGF-2 and insulin-mediated signaling at clinically relevant levels.
- Total addressable US market for tumor HI est. at ~4,500 patients (1,500 ICTH + 3,000 NICTH).
- Company evaluating registrational study in tumor HI including both ICTH and NICTH after positive Jan 2024 FDA interaction.
- RZ358 already in Phase 3 for congenital HI; has Orphan Drug Designations in US/EU for multiple indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924033068/0001104659-24-033068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924033068/tm248506d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer